C4 Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Watertown, MA
CCCC chart
What traders are saying about $CCCC
Latest postsC4 Therapeutics, Inc. news
- Could You Have Seen The Run In Kymera Stock Coming?
trefis.com ·
- C4 Therapeutics, Inc. Estimates – NASDAQ:CCCC
TradingView ·
- CCCC Q3'26 Earnings: revenue estimate is 8.85M USD
TradingView ·
- Insmed Appoints Two New Directors to Its Board
Yahoo Finance ·
- Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Yahoo Finance ·
- C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Yahoo Finance ·
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Yahoo Finance ·
- C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
Yahoo Finance ·
- Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Yahoo Finance ·
- C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance ·
- C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance ·
- Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Yahoo Finance ·
C4 Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M |
| Net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M |
| Diluted EPS | $-1.27 | $-1.52 | $-2.67 | $-2.62 |
| Total assets (year end) | $359.1M | $349.6M | $376.5M | $430.8M |
| Cash and equivalents (year end) | $74.6M | $55.5M | $126.6M | $29.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About C4 Therapeutics, Inc.
- Ticker
- CCCC (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Watertown, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1662579
Frequently asked questions
What exchange is C4 Therapeutics, Inc. listed on?
C4 Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CCCC.
What industry is C4 Therapeutics, Inc. in?
C4 Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is C4 Therapeutics, Inc. headquartered?
C4 Therapeutics, Inc.'s business address on file with the SEC is in Watertown, MA.
When does C4 Therapeutics, Inc.'s fiscal year end?
C4 Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did C4 Therapeutics, Inc. report?
C4 Therapeutics, Inc. reported $35.9M in revenue for calendar year 2025, according to its SEC filings.